Efficacy and Safety of Trastuzumab Deruxtecan in the Treatment of HER2-Low/Positive Advanced Breast Cancer: A Single-Arm Meta-Analysis

    June 2023 in “ Frontiers in Pharmacology ”
    Zongyu Li, Shangwen Guo, Haoyi Xue … He Zhu
    Studysummary This meta-analysis reports that trastuzumab deruxtecan is effective and has an acceptable safety profile for treating HER2-low or positive advanced breast cancer, although further research is recommended to support individualized treatment strategies.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on frontiersin.org →
    Discuss this study in the Community →